Modified mRNA for BMP-2 in Combination with Biomaterials Serves as a Transcript-Activated Matrix for Effectively Inducing Osteogenic Pathways in Stem Cells

Stem Cells and Development

Volumn 26, Issue 1, 2017, Pages 25-34

  Balmayor, Elizabeth R ^a,b   Geiger, Johannes P ^b   Koch, Christian ^b   Aneja, Manish K ^b   Van Griensven, Martijn ^a   Rudolph, Carsten ^b   Plank, Christian ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ETHRIS GMBH   (Germany)

Author keywords

biomaterials; Biphasic calcium phosphate; BMP 2; Chemically modified mRNA; Fibrin; MRNA delivery; Transcript activated matrices

Indexed keywords

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE; COLLAGEN TYPE 1; ENHANCED GREEN FLUORESCENT PROTEIN; FIBRIN; LUCIFERASE; MESSENGER RNA; OSTEOCALCIN; BMP2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE REGENERATION; CONTROLLED STUDY; FEMALE; GEL; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL; STEM CELL CULTURE; ANIMAL; BONE MINERALIZATION; DRUG EFFECTS; GENETICS; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CALCIUM PHOSPHATES; FEMALE; FIBRIN; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFECTION;

EID: 85007418165     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2016.0171     Document Type: Article

References (39)

1. Ciavarella S, M Dominici, F Dammacco and F Silvestris. (2011). Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev 20:1-10.
2. Jalali M, WN Kirkpatrick, MG Cameron, S Pauklin and L Vallier. (2014). Human stem cells for craniomaxillofacial reconstruction. Stem Cells Dev 23:1437-1451.
3. Shiota G and N Itaba. (2016). Progress in stem cell-based therapy for liver disease. Hepatol Res [Epub ahead of print]; DOI: 10.1111/hepr.12747.
4. Zhao K and Q Liu. (2016). The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol 9:46.
5. Lo KW, KM Ashe, HM Kan and CT Laurencin. (2012). The role of small molecules in musculoskeletal regeneration. Regen Med 7:535-549.
6. Barrientos S, H Brem, O Stojadinovic and M Tomic-Canic. (2014). Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen 22:569-578.
7. Jeffcoate WJ and FL Game. (2014). Evidence for the use of biological therapies in ulcers of the foot in diabetes. Bio-Drugs 28:1-6.
8. Carragee EJ, EL Hurwitz and BK Weiner. (2011). A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11:471-491.
9. Dinh T, S Braunagel and BI Rosenblum. (2015). Growth factors in wound healing: the present and the future? Clin Podiatr Med Surg 32:109-119.
10. Chrastil J, JB Low, PG Whang and AA Patel. (2013). Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine. Spine (Phila Pa 1976) 38: E1020-E1027.
11. Epstein NE. (2013). Complications due to the use of BMP/ INFUSE in spine surgery: the evidence continues to mount. Surg Neurol Int 4:S343-S352.
12. Devine JG, JR Dettori, JC France, E Brodt and RA McGuire. (2012). The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J 3:35-41.
13. FDA Public Health Notification: Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealth Notifications/ucm062000.htm. Accessed May 29, 2016.
14. FDA Public Health Notification: FDA Announces New Labeling Changes for Regranex. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116909.htm. Accessed May 29, 2016.
15. Balmayor ER, JP Geiger, MK Aneja, T Berezhanskyy, M Utzinger, O Mykhaylyk, C Rudolph and C Plank. (2016). Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats. Biomaterials 87:131-146.
16. Elangovan S, B Khorsand, AV Do, L Hong, A Dewerth, M Kormann, RD Ross, D Rick Sumner, C Allamargot and AK Salem. (2015). Chemically modified RNA activated ma-trices enhance bone regeneration. J Control Release 218: 22-28.
17. Kormann MS, G Hasenpusch, MK Aneja, G Nica, AW Flemmer, S Herber-Jonat, M Huppmann, LE Mays, M Illenyi, et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29:154-157.
18. Balmayor ER, M Flicker, T Käser, A Saalmüller and RG Erben. (2013). Human placental alkaline phosphatase as a tracking marker for bone marrow mesenchymal stem cells. Biores Open Access 2:346-355.
19. Kim J, SH Lee, J Choe and TG Park. (2009). Intracellular small interfering RNA delivery using genetically engineered double-stranded RNA binding protein domain. J Gene Med 11:804-812.
20. Xing R, G Liu, Q Quan, A Bhirde, G Zhang, A Jin, LH Bryant, A Zhang, A Liang, et al. (2011). Functional MnO nanoclusters for efficient siRNA delivery. Chem Commun (Camb) 47:12152-12154.
21. Inouye S, Y Sahara-Miura, J Sato, R Iimori, S Yoshida and T Hosoya. (2013). Expression, purification and luminescence properties of coelenterazine-utilizing luciferases from Renilla, Oplophorus and Gaussia: comparison of substrate specificity for C2-modified coelenterazines. Protein Expr Purif 88:150-156.
22. Pavlovic M, J Mayfield and B Balint. (2013). Tissue engineering triangle and its development. In: Handbook of Medical and Healthcare Technologies. Furht B and A Agarwal, eds. Springer, New York, pp 267-282.
23. Evans CH. (2012). Gene delivery to bone. Adv Drug Deliv Rev 64:1331-1340.
24. Reautschnig P, P Vogel and T Stafforst. (2016). The notorious R.N.A. in the spotlight - drug or target for the treatment of disease. RNA Biol [Epub ahead of print]; DOI: 10.1080/15476286.2016.1208323.
25. Holtkamp S, S Kreiter, A Selmi, P Simon, M Koslowski, C Huber, O Tureci and U Sahin. (2006). Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108:4009-4017.
26. Le Guehennec L, P Layrolle and G Daculsi. (2004). A review of bioceramics and fibrin sealant. Eur Cell Mater 8:1-11.
27. Goyenvalle E, E Aguado, P Pilet and G Daculsi. (2010). Biofunctionality of MBCP ceramic granules (TricOs) plus fibrin sealant (Tisseel) versus MBCP ceramic granules as a filler of large periprosthetic bone defects: an investigative ovine study. J Mater Sci Mater Med 21:1949-1958.
28. Wagner W, J Wiltfang, H Pistner, M Yildirim, B Ploder, M Chapman, N Schiestl and E Hantak. (2012). Bone formation with a biphasic calcium phosphate combined with fibrin sealant in maxillary sinus floor elevation for delayed dental implant. Clin Oral Implants Res 23:1112-1117.
29. Morton TJ, W Furst, M van Griensven and H Redl. (2009). Controlled release of substances bound to fibrin-anchors or of DNA. Drug Deliv 16:102-107.
30. Lei P, RM Padmashali and ST Andreadis. (2009). Cellcontrolled and spatially arrayed gene delivery from fibrin hydrogels. Biomaterials 30:3790-3799.
31. Bose S and S Tarafder. (2012). Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review. Acta Biomater 8:1401-1421.
32. Badieyan ZS, T Berezhanskyy, M Utzinger, MK Aneja, D Emrich, R Erben, C Schuler, P Altpeter, M Ferizi, et al. (2016). Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration. J Control Release 239:137-148.
33. Schillinger U, G Wexel, C Hacker, M Kullmer, C Koch, M Gerg, S Vogt, P Ueblacker, T Tischer, et al. (2008). A fibrin glue composition as carrier for nucleic acid vectors. Pharm Res 25:2946-2962.
34. Plank C, D Eglin, N Fahy, C Sapet, P Borget, G van Osch, C Gentili, T Miramond, K Zöller and M Anton. (2012). Gene activated matrices for bone and cartilage regeneration in arthritis. Eur J Nanomed 4:17-32.
35. des Rieux A, A Shikanov and LD Shea. (2009). Fibrin hydrogels for non-viral vector delivery in vitro. J Control Release 136:148-154.
36. Xie Y, ST Yang and DA Kniss. (2001). Three-dimensional cell-scaffold constructs promote efficient gene transfection: implications for cell-based gene therapy. Tissue Eng 7: 585-598.
37. Whitehead KA, R Langer and DG Anderson. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129-138.
38. Jarzebinska A, T Pasewald, J Lambrecht, O Mykhaylyk, L Kummerling, P Beck, G Hasenpusch, C Rudolph, C Plank and C Dohmen. (2016). A single methylene group in oligoalkylamine-based cationic polymers and lipids promotes enhanced mRNA delivery. Angew Chem Int Ed Engl 55:9591-9595.
39. Kauffman KJ, MJ Webber and DG Anderson. (2015). Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release [Epub ahead of print]; DOI: 10.1016/j.jconrel.2015.12.032.